Finance

Senarai
JAZZ:NASDAQ
Jazz Pharmaceuticals PLC
USD 243.59
+1.15%
(+2.76) 1H
USD 243.20
-0.16% (-0.39)
Prapasaran
Ditutup: 16 Sep, 4:00:01 PTG GMT-4  ·   USD
Semua simbol
SimbolHargaPerubahan% Perubahan
Menjana cerapan popular untuk JAZZ...
Buka
USD 242.93
Tinggi
USD 244.36
Rendah
USD 241.76
Permodalan Pasaran
15.81B
Purata volum
956.11K
Volum
2.66K
Nisbah H/P
16.66
tgi 52 mgu
USD 266.38
rdh 52 mgu
USD 125.78
EPS
USD 14.63
Beta
0.36
Syer tertunggak
64.92J
Bilangan pekerja
3K
Buka
USD 242.93
Tinggi
USD 244.36
Rendah
USD 241.76
Permodalan Pasaran
15.81B
Purata volum
956.11K
Volum
2.66K
Nisbah H/P
16.66
tgi 52 mgu
USD 266.38
rdh 52 mgu
USD 125.78
EPS
USD 14.63
Beta
0.36
Syer tertunggak
64.92J
Bilangan pekerja
3K
Cerita berita
Daripada sumber web dan rakan kongsi berita
Profil
Jazz Pharmaceuticals plc is an American global biopharmaceutical company with a focus on oncology and neuroscience. It was founded in 2003 in California, United States and is now headquartered in Dublin, Ireland. One of the company's considerable products is the United States Food and Drug Administration approved drug Xyrem, the sodium salt of the naturally occurring neurotransmitter γ-Hydroxybutyric acid. In 2017, net product sales of Xyrem were $1.187 billion, which represented 74% of the company's total net product sales. In 2019, Jazz was granted FDA-approval to market Sunosi with indications for treating excessive daytime sleepiness in narcolepsy as well as obstructive sleep apnea. In 2022, it was announced that Axsome Therapeutics would be acquiring Sunosi from Jazz Pharmaceuticals. In 2007, the company pled guilty to felony charges related to its illegal marketing of Xyrem for off-label use. The company is also a member of the Pharmaceutical Research and Manufacturers of America. Wikipedia
Perihal Jazz Pharmaceuticals PLC
CEOBruce C Cozadd
Pekerja2.89K
Diasaskan2003
Ibu pejabat-
Sektor-
Rating penganalisis
Berdasarkan 16 penganalisis yang memberikan rating saham kepada JAZZ dalam tempoh 3 bulan yang lalu
Belian kuat
Beli
16
Pegang
0
Jual
0
Ramalan 12 bulan
Berdasarkan 16 penganalisis Wall Street yang menawarkan sasaran harga 12 bulan untuk JAZZ dalam tempoh 3 bulan yang lalu.
Tertinggi
Semasa USD 243.59
USD 337.00 (+38.35%)
Purata
USD 297.93 (+22.31%)
Terendah
USD 271.00 (+11.25%)
Penganalisis
Syor
Tindakan
Sasaran harga
Diunjurkan
Tarikh
Ashwani Verma
UBS
Buy
Reiterated
USD 337.00
+38.3%
09/14/2026
Etzer Darout
Barclays
Buy
Maintained
USD 271.00
+11.3%
09/10/2026
David Amsellem
Piper Sandler
Buy
Reiterated
USD 310.00
+27.3%
09/09/2026
Gary Nachman
Canaccord Genuity
Buy
Maintained
USD 300.00
+23.2%
08/31/2026
Gregory Renza
Truist Financial
Buy
Maintained
-
-
09/01/2026
Joseph Thome
TD Cowen
Buy
Maintained
USD 300.00
+23.2%
08/31/2026
Ami Fadia
Needham
Buy
Reiterated
USD 310.00
+27.3%
08/31/2026
Leonid Timashev
RBC Capital
Buy
Maintained
USD 299.00
+22.7%
08/28/2026
Sean Laaman
Morgan Stanley
Buy
Reiterated
USD 322.00
+32.2%
08/26/2026
Jason Gerberry
Bank of America Securities
Buy
Maintained
USD 307.00
+26%
08/25/2026
David Hoang
Deutsche Bank
Buy
Maintained
USD 300.00
+23.2%
08/26/2026
Mohit Bansal
Wells Fargo
Buy
Maintained
USD 300.00
+23.2%
08/10/2026
Annabel Samimy
Stifel Nicolaus
Buy
Reiterated
USD 275.00
+12.9%
08/04/2026
Jessica Fye
J.P. Morgan
Buy
Reiterated
USD 276.00
+13.3%
08/04/2026
Brian Skorney
Robert W. Baird
Buy
Maintained
USD 280.00
+14.9%
08/04/2026
Unknown Analyst
Jefferies
Buy
Maintained
USD 282.00
+15.8%
07/13/2026
Joon Lee
Truist Financial
Buy
Initiated
USD 256.00
+5.1%
06/09/2026
Jeffrey Walch
Bernstein
Hold
Reiterated
USD 229.00
-6%
06/08/2026
Unknown Analyst
Bernstein
Hold
Maintained
-
-
06/01/2026
Unknown Analyst
J.P. Morgan
Buy
Maintained
USD 265.00
+8.8%
05/20/2026
Tiago Fauth
Raymond James
Buy
Maintained
USD 239.00
-1.9%
05/06/2026
Unknown Analyst
Raymond James
Buy
Maintained
USD 239.00
-1.9%
05/06/2026
Laporan terakhir
3 Ogo 2026
Tempoh fiskal
S2 2026
EPS / Anggaran (USD)
USD 5.71 / USD 6.18
-7.54%tersasar
Hasil / Anggaran (USD)
1.21B / 1.11B
+8.43%melebihi
Panggilan persidangan pendapatan fiskal Suku Ke-2 2026
Menunggu panggilan persidangan pendapatan
Sekilas pandang
Cerapan daripada berita dan laporan terkini
Laporan sebelumnyaSemua nilai dalam USD
Loading Previous Earnings...
Penyata pendapatan
Hasil
Pendapatan bersih
Semua nilai dalam USD
Sep 2025
Dis 2025
Mac 2026
Jun 2026
Hasil
1.13B
1.20B
1.07B
1.21B
Kos barangan yang dijual
128.88J
112.92J
96.60J
116.40J
Kos hasil
128.88J
112.92J
96.60J
116.40J
Perbelanjaan penyelidikan dan pembangunan
198.20J
172.66J
196.00J
207.50J
Jumlah perbelanjaan penyelidikan dan pembangunan
-
-
-
-
Perbelanjaan jualan, am dan pentadbiran
379.15J
418.46J
352.70J
389.20J
Belanja kendalian
745.72J
760.86J
721.00J
766.70J
Jumlah belanja kendalian
874.60J
873.79J
817.60J
883.10J
Pendapatan kendalian
251.51J
324.14J
251.30J
325.20J
Pendapatan bukan kendalian lain
-
-
122.80J
-
EBT termasuk item luar biasa
8.99J
208.41J
299.20J
210.90J
EBT tidak termasuk item luar biasa
202.99J
278.02J
336.70J
287.90J
Belanja cukai pendapatan
-242.42J
4.96J
6.10J
18.10J
Kadar cukai berkesan
-2,697.20%
2.38%
2.04%
8.58%
Belanja kendalian lain
-
-
-
-
Pendapatan bersih
251.41J
203.45J
293.10J
192.80J
Margin untung bersih
22.33%
16.98%
27.42%
15.96%
Perolehan bagi setiap syer
8.13
6.64
6.34
5.71
Pendapatan faedah dan pelaburan
18.60J
20.50J
23.40J
25.30J
Belanja faedah
-67.18J
-65.91J
-63.30J
-62.40J
Belanja faedah bersih
-48.58J
-45.41J
-39.90J
-37.10J
Caj susut nilai dan pelunasan
-
-
-
-
EBITDA
429.76J
503.31J
432.70J
504.30J
Keuntungan atau kerugian daripada jualan aset
-
-
-
-
Transaksi orang dalam
Data transaksi orang dalam diperoleh daripada sumber pihak ketiga. Ketahui lebih lanjut
Orang dalam
Jawatan
Jenis
Tarikh
Saham
Jumlah
Halaman 1
Kandungan AI boleh mengandungi kesilapan. Ketahui lebih lanjut
BantuanHantar maklum balasPrivasiSyaratPenafian
Apl Google